SNCA and Parkinson disease: However, for a disease like PD affecting the basal ganglia and other discrete regions of the brain primarily, the changes in the level of α-synuclein may be manifested consistently only in cerebrospinal fluid (CSF), and this may impede its use as a promising biomarker for PD.